S&P 500

5.321,41

0,25%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Acasti Pharma Inc (ACST)
Acasti Pharma Inc (ACST) Notícias

ACST

Acasti Pharma (ACST)

Acasti Pharma Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ACST

1 2 3 4 5 6 7 8 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
10/05/2024	17:11	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:ACST	Acasti Pharma Inc
08/05/2024	20:19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACST	Acasti Pharma Inc
12/02/2024	10:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACST	Acasti Pharma Inc
12/02/2024	09:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ACST	Acasti Pharma Inc
08/01/2024	10:00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ACST	Acasti Pharma Inc
17/10/2023	01:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ACST	Acasti Pharma Inc
16/10/2023	17:31	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ACST	Acasti Pharma Inc
10/10/2023	08:40	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:ACST	Acasti Pharma Inc
06/10/2023	17:30	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ACST	Acasti Pharma Inc
25/08/2023	18:01	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ACST	Acasti Pharma Inc
25/08/2023	17:21	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ACST	Acasti Pharma Inc
25/08/2023	17:15	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ACST	Acasti Pharma Inc
10/07/2023	10:00	PR Newswire (US)	Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients	NASDAQ:ACST	Acasti Pharma Inc
07/07/2023	09:00	PR Newswire (US)	Acasti Pharma Announces 1-for-6 Reverse Stock Split	NASDAQ:ACST	Acasti Pharma Inc
05/07/2023	10:00	PR Newswire (US)	Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023	NASDAQ:ACST	Acasti Pharma Inc
23/06/2023	08:02	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:ACST	Acasti Pharma Inc
23/06/2023	08:00	PR Newswire (US)	Acasti Pharma Reports Fiscal Year 2023 Operational Results	NASDAQ:ACST	Acasti Pharma Inc
22/06/2023	10:00	PR Newswire (US)	Acasti Announces Appointment of New Scientific Advisory Board Members	NASDAQ:ACST	Acasti Pharma Inc
26/05/2023	16:07	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ACST	Acasti Pharma Inc
17/05/2023	10:00	PR Newswire (US)	Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference	NASDAQ:ACST	Acasti Pharma Inc
08/05/2023	08:00	PR Newswire (US)	Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025	NASDAQ:ACST	Acasti Pharma Inc
05/04/2023	18:01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ACST	Acasti Pharma Inc
04/04/2023	09:01	PR Newswire (US)	Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND	NASDAQ:ACST	Acasti Pharma Inc
04/04/2023	09:00	PR Newswire (US)	Acasti Announces Appointment of Prashant Kohli as CEO	NASDAQ:ACST	Acasti Pharma Inc
30/03/2023	09:30	PR Newswire (US)	Acasti Pharma Inc. Announces the Resignation of a Director	NASDAQ:ACST	Acasti Pharma Inc
13/03/2023	09:00	PR Newswire (US)	Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange	NASDAQ:ACST	Acasti Pharma Inc
08/03/2023	11:00	PR Newswire (US)	Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference	NASDAQ:ACST	Acasti Pharma Inc
28/02/2023	15:00	PR Newswire (US)	Acasti Pharma Recognizes Rare Disease Day	NASDAQ:ACST	Acasti Pharma Inc
14/02/2023	09:02	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ACST	Acasti Pharma Inc
14/02/2023	09:00	GlobeNewswire Inc.	Acasti Pharma Reports Third Quarter 2023 Operational Results	NASDAQ:ACST	Acasti Pharma Inc